Welcome to the international HTA database

Showing [20828 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of acute lower GI bleeding
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023	NIHR Health Technology Assessment programme	Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023	NIHR Health Technology Assessment programme	Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Trends in utilisation of ultrasound by older Australians (2010-2019)
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023	NIHR Health and Social Care Delivery Program	Mental health crisis care for children and young people aged 5 to 25 years: the CAMH-Crisis evidence synthesis
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Extracorporeal shock wave therapy for orthopaedic indications]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NGAL assay for the detection of acute kidney injury]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NK cell degranulation (natural killer)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: impact of physical activity on the adverse effects of cancer and cancer treatments in adults]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: analysis of personal and clinical characteristics associated with a favourable response to psychosocial interventions aimed at preventing and treating common mental disorders and symptoms]
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Interventions to prevent and reduce gang-related crime among children and young adults
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (breast cancer, adjuvant) - Addendum to Commission A22-89]
2023	Scottish Health Technologies Group (SHTG)	Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023	Scottish Health Technologies Group (SHTG)	Store-and-forward teledermatology for triage of primary care referrals
2023	Scottish Health Technologies Group (SHTG)	Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023	Scottish Health Technologies Group (SHTG)	An assessment of the Feeling Good app
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	Scottish Health Technologies Group (SHTG)	Living donor transplantation
2023	Scottish Health Technologies Group (SHTG)	Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023	Scottish Health Technologies Group (SHTG)	Community based respiratory care services for patients with chronic respiratory conditions
2023	Scottish Health Technologies Group (SHTG)	Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	NIHR Health Technology Assessment programme	Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023	NIHR Health Technology Assessment programme	Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Early detection tools for emotional distress in adult people with cancer]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Evaluation of the lung cancer screening program]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023	NIHR Health Technology Assessment programme	Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: cryotherapy for the prevention of taxane-induced peripheral neuropathy]
2023	Agency for Care Effectiveness (ACE)	Echinocandins for treating invasive candidiasis
2023	Agency for Care Effectiveness (ACE)	Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023	Agency for Care Effectiveness (ACE)	Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023	Agency for Care Effectiveness (ACE)	Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: characteristics and needs of targeted rehabilitation clienteles for young people with adjustment problems aged 10 or older]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for intellectual disability and global developmental delay - Assessment report on the repatriation of a test performed outside Québec]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Rebinyn – prophylaxis in children and adolescents with hemophilia B]
2023	Health Information and Quality Authority (HIQA)	A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023	Health Information and Quality Authority (HIQA)	Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: barriers and facilitators encountered by women living with a physical disability (PD), intellectual disability (ID) or autism spectrum disorder (ASD) when using perinatal services]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relugolix (prostate cancer) - Benefit assessment acc. to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (renal cell carcinoma) - Addendum to Commission A22-71]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2023	Belgian Health Care Knowledge Centre (KCE)	Evaluation of digital medical technologies
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023	Scottish Health Technologies Group (SHTG)	Bacteriophage therapy for patients with difficult to treat bacterial infections
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: wound care-assessment, management, and optimal treatment use]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Norwegian Institute of Public Health (NIPH)	[Triclosan coated sutures for prevention of surgical site infection - Protocol for health technology assessment - project description]
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	Norwegian Institute of Public Health (NIPH)	Health technology assessment of 177Lu- PSMA-617 treatment for metastatic castration resistant prostate cancer - Protocol for Health technology assessment - project description
2023	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Evondos® medicine-dispensing service
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for total knee replacement]
2023	Ontario Health	Supplemental breast screening for people with dense breasts